Technology ID
TAB-4487

Isotopes of Alpha Ketoglutarate and Related Compounds for Hyperpolarized MRI Imaging

E-Numbers
E-070-2020-0
Lead Inventor
Swenson, Rolf (NHLBI)
Co-Inventors
Sail, Deepak (NHLBI)
Applications
Software / Apps
Diagnostics
Therapeutic Areas
Oncology
Development Stages
Pre-clinical (in vivo)
Research Products
Research Equipment
Computational models/software
Lead IC
NHLBI
ICs
NHLBI

This technology includes 1-13C-ketoglutarate which can be used for imaging the conversion to hydroxyglutarate (HG) or Gln in cancer cells with an IDH1 mutations by hyperpolarized MRI. The ability to detect the status of IDH1 mutations is clinically prognostic for multiple cancers. These exciting observations are limited by two factors, the major one being that the natural abundance of 13C at position C5 overlaps with 1-13C-2-hydroxyglutarate peak, which limits the sensitivity of analysis and prevents simultaneous observations of HG and Gln formation. The other issue is that the ketoglutarate is not cell permeable. This invention provides a solution and enhances the utility of this imaging approach.

Commercial Applications
Diagnostic imaging agent with potential for validating cancer treatment options.

Competitive Advantages
An improved hyperpolarized MRI tracer for prognostic imaging of cancer.
Licensing Contact:
Shmilovich, Michael
shmilovm@nih.gov